-
Mashup Score: 2REACH3 Analysis: Patient-Reported cGVHD Improvement Correlated With Overall Response, TSS Response | Blood Cancers Today - 6 day(s) ago
Patient-reported response is associated with overall response, total symptom score response, and failure-free survival in patients with chronic GVHD.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
Modern clinical trials are investigating novel drug combinations with ruxolitinib and other JAK inhibitors to improve patient outcomes.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
💬 At #ASH24, Drs. Kapila Viges (@MPN_RF) and John Mascarenhas (@IcahnMountSinai) discussed how ongoing research, such as the phase III SENTRY trial, aims to fill gaps in #myelofibrosis care. ➡️ Don't miss it! https://t.co/8ahF85zdrR https://t.co/2kPpL9AfSM
-
-
Mashup Score: 0Salvia Jain Lab's PETAL Consortium Unveils Novel Scoring System for T-Cell Lymphoma | Blood Cancers Today - 6 day(s) ago
Researchers from the Salvia Jain Lab have developed a new scoring system, called the PIRT score, using one of the largest global cohorts of patients with T-cell lymphoma.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📋 Researchers from the Salvia Jain Lab at @MGHCancerCenter have developed a novel scoring system to predict outcomes for newly diagnosed, relapsed or refractory T-cell lymphomas. 💡 Learn more: https://t.co/iaFePUSToH https://t.co/9mRvlU6jHG
-
-
Mashup Score: 0
Jeff P. Sharman, MD, discusses unmet needs, prognosis, and innovative treatments like pirtobrutinib in the evolving landscape of chronic lymphocytic leukemia.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🙌 We recently spoke with @jeff_sharman, of @TheUSONetwork, who discussed the evolving treatment landscape for #CLL, unmet needs in CLL management, and the current prognosis for CLL patients. 📺 Watch here! https://t.co/cilyVCllmu https://t.co/ZlQEI8uoQF
-
-
Mashup Score: 3Advancing Treatment Evaluation With Surrogate End Points in MM | Blood Cancers Today - 10 day(s) ago
Kapila Viges, MD, and John Mascarenhas, MD, discuss the role of surrogate end points in multiple myeloma clinical trials.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
⭐ Kapila Viges, MD (@MPN_RF) and John Mascarenhas, MD, (@IcahnMountSinai), discussed the role of surrogate end points in multiple #myeloma clinical trials at #ASH2024. 📺 Watch here! https://t.co/qUKkal8K1R https://t.co/tp3tT1XwNc
-
-
Mashup Score: 0KOMET-001 Phase II Trial Results Encouraging for Ziftomenib Monotherapy in NPM1-Mutant AML | Blood Cancers Today - 10 day(s) ago
A new study protocol plans for two phase III trials to evaluate the agent in intensive and nonintensive combinations for AML.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
The phase II KOMET-001 trial has reported promising results for ziftomenib monotherapy in relapsed or refractory NPM1-mutant #AML, according to a press release from @kuraoncology. 📰 Read more: https://t.co/4z4fm6brUz https://t.co/1j4cVlivRN
-
-
Mashup Score: 2Video Insights | Blood Cancers Today - 11 day(s) ago
Watch expert interviews from leading hematologists and oncologists on Blood Cancers Today.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
TGIF 😍 If you're looking for something to do this weekend, why not catch up on our video interviews? @TaylorJ_MD, @SanjayPatelMD, @paurotero, @leshune, and other experts discuss all the latest in #multiplemyeloma, #CLL, and more! 📺 https://t.co/jvcKJQ9DD7 https://t.co/OU6Ek5qp0U
-
-
Mashup Score: 8Linvoseltamab Now Under FDA Review as a Potential Treatment Option for RRMM | Blood Cancers Today - 11 day(s) ago
The FDA has accepted a BLA for linvoseltamab for the treatment of adult patients with relapsed or refractory multiple myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
The FDA has accepted a BLA for linvoseltamab for R/R myeloma in the fourth-line setting or for patients who are in the third-line setting and are refractory to the last line of therapy. Read more about the approval, with insight from @JoshuaRichterMD. ➡️ https://t.co/Ft05VJvb7W https://t.co/iA7Qu4ZbOt
-
-
Mashup Score: 11Natalie Callander, MD, on Selinexor in Myeloma: Triplet Combinations, Dosing, Efficacy | Blood Cancers Today - 11 day(s) ago
Natalie Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
We recently spoke with @nsc_natalie, of @UWCarbone, on selinexor, pomalidomide, and dexamethasone for the treatment of relapsed or refractory multiple #myeloma. 📺 Watch here! https://t.co/6VHTA7uyUo https://t.co/n2ViQ871Iv
-
-
Mashup Score: 2Olutasidenib and Azacitidine Combination Expands Options for mIDH1 Relapsed or Refractory AML | Blood Cancers Today - 12 day(s) ago
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant AML treated with combination of olutasidenib plus azacitidine in multiple studies.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant #AML treated with the experimental combination of olutasidenib and azacitidine, according to a study led by @GCC_Cortes of @GACancerCenter. 📰 Read more: https://t.co/H2s214uvEf https://t.co/kLaY4S0xH9
-
Patient-reported responses in chronic GVHD improvement were associated with overall response, TSS response, and failure-free survival in an analysis of the REACH3 trial presented at #Tandem25 by @joseph_pidala of @MoffittNews. 📰 Read more: https://t.co/jsEi8dpKKi https://t.co/OOQtAuxYqK